Citadel Advisors LLC Invests $49,000 in RenovoRx, Inc. (NASDAQ:RNXT)

Citadel Advisors LLC acquired a new stake in RenovoRx, Inc. (NASDAQ:RNXT) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 37,757 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned about 0.16% of RenovoRx at the end of the most recent reporting period.

Separately, Renaissance Technologies LLC acquired a new stake in shares of RenovoRx in the 4th quarter valued at $84,000. 3.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Ascendiant Capital Markets boosted their price target on RenovoRx from $11.00 to $11.50 and gave the stock a “buy” rating in a report on Thursday, June 5th. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of RenovoRx in a research report on Monday, May 19th. Finally, Wall Street Zen raised RenovoRx to a “sell” rating in a research note on Friday, June 6th.

Insider Activity

In other RenovoRx news, insider Ramtin Agah bought 21,000 shares of the business’s stock in a transaction that occurred on Thursday, June 5th. The shares were acquired at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the transaction, the insider now directly owns 734,460 shares in the company, valued at approximately $1,028,244. This represents a 2.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought 128,145 shares of company stock valued at $119,619 over the last quarter. 9.13% of the stock is owned by company insiders.

RenovoRx Price Performance

Shares of RenovoRx stock opened at $1.36 on Thursday. The company’s 50 day moving average price is $1.09 and its two-hundred day moving average price is $1.16. The firm has a market capitalization of $49.74 million, a P/E ratio of -2.39 and a beta of 1.32. RenovoRx, Inc. has a fifty-two week low of $0.75 and a fifty-two week high of $1.69.

RenovoRx (NASDAQ:RNXT) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.23 million. On average, analysts expect that RenovoRx, Inc. will post -0.4 earnings per share for the current year.

RenovoRx Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.